Angiogenesis in lymphoproliferative disorders

Acta Haematologica

Volumn 106, Issue 4, 2001, Pages 184-189

  Salven, Petri ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Angiogenesis; Fibroblast growth factor, basic; Leukemia; Lymphoma; Lymphoproliferative disorders; Malignancies, hematological; Multiple myeloma; Vascular endothelial growth factor

Indexed keywords

ARSENIC TRIOXIDE; BASIC FIBROBLAST GROWTH FACTOR; ENDOSTATIN; INTERLEUKIN 12; NEUTRALIZING ANTIBODY; THALIDOMIDE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; HUMAN; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SOLID TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; GROWTH SUBSTANCES; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0035704958     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046615     Document Type: Article

References (89)

1. Angiogenesis in the female reproductive system
2. Angiogenesis in cancer, vascular, rheumatoid and other disease
3. Differentiation of endothelium
4. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
5. Angiogenesis: Potential for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation
6. Clinical applications of angiogenic growth factors and their inhibitors
7. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation
8. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
9. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
10. Tumour angiogenic factor associated with subcutaneous lymphoma
11. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
12. Evidence of increased angiogenesis in patients with acute myeloid leukemia
13. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
14. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
15. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study
16. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas
17. Angiogenesis in cutaneous lymphoproliferative disorders: Microvessel density discriminates between cutaneous B-cell lymphomas and B-cell pseudolymphomas
18. Angiogenesis is an early event in the generation of myc-induced lymphomas
19. Angiogenesis in myelodysplastic syndromes
20. Bone marrow angiogenesis and progression in multiple myeloma
21. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
22. Prognostic value of bone marrow angiogenesis in multiple myeloma
23. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization
24. Vascular-specific growth factors and blood vessel formation
25. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
26. The biology of vascular endothelial growth factor
27. Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction
28. Biological roles of fibroblast growth factor-2
29. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells
30. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells
31. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma
32. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
33. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121
34. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
35. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor
36. Vascular endothelial growth factor (VEGF) and its receptors
37. Regulation of angiogenesis via vascular endothelial growth factor receptors
38. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis
39. Vascular endothelial growth factor in squamous cell head and neck carcinoma: Expression and prognostic significance
40. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor
41. Endotoxins induce and interferon-α suppresses VEGF production in human peripheral blood mononuclear cells
42. Intracellular pool of vascular endothelial growth factor in human neutrophils
43. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
44. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation
45. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
46. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients
47. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
48. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia
49. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels
50. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
51. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease
52. Vascular endothelial growth factor, a possible paracrine in human acute myeloid leukemias
53. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
54. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
55. Atypical lymphoproliferative disorders
56. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
57. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
58. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: Frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production
59. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells
60. Constitutive and selective expression of basic fibroblast growth factor in human leukaemia cell lines
61. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: A potential pathologic role
62. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: Differential production and release by CD4+ and CD8+ T cells
63. Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia
64. Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis
65. Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells
66. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine
67. A high pre-treatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma
68. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
69. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels
70. Thalidomide is an inhibitor of angiogenesis
71. Antitumor activity of thalidomide in refractory multiple myeloma
72. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
73. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent
74. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
75. Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug
76. Thalidomide in the treatment of relapsed multiple myeloma
77. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients
78. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
79. Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia
80. Arsenic and alltrans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia
81. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
82. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
83. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
84. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma
85. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
86. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
87. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth
88. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12
89. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma